Result on whether someone is a carrier of the new coronavirus comes out in 90 minutes, against 24 hours of current laboratory tests, ένα νέο μοριακό τεστ διάγνωσης της Covid-19, which seems to be very reliable, showing sensitivity over 94% (so it gives very few false negative results) and specialty 100% (no false positive results), as announced by scientists in Britain.
The test was developed by DnaNudge, a new techno-germ company of Imperial College, according to AMPE. He is the co-founder and CEO of the company Greek-Cypriot professor Chris Toumazou, electrical engineer and innovative inventor, founder of the Imperial Institute of Biomedical Engineering. His colleague, co-founder of 2015 of DnaNudge and is a lead scientist the Greek Dr. Maria Karvela, graduate of the Department of Biology of the University of Athens, with a PhD from the University of Glasgow.
Researchers at Imperial College London, led by Infectious Diseases Professor Graham Cook, who published in The Lancet Microbe, tried the test on 386 patients and medical staff of the British National Health System.
The test, by taking a sample from the nose and then detecting traces of coronavirus genetic material, does not require a lab and can be run on a mobile device smaller than a mobile phone, as explained by AMPE. It has already started to be used in eight London hospitals and its use is to be extended throughout Britain. The British government has already ordered for 5,8 millions of such value tests 161 million. pounds.
"Many tests necessarily sacrifice accuracy for the sake of speed or vice versa, but the new test manages to combine both ", said Cook.
As stated by Toumazou, "The DnaNudge test offers very important possibilities for mass control of the population during the pandemic Covid-19. It is suitable for performing tests in medical and non-medical environments, such as nursing homes, schools, transport nodes, offices, even theaters ". Nevertheless, before this happens, further studies of the test should be performed.
Researchers are even trying to further develop the test, to detect influenza A and B viruses simultaneously, together with the new coronavirus SARS-CoV-2.